… for short to intermediate-length lesions in the SFA, with 1-year patency … Paclitaxel-eluting
drug-coated balloons (DCBs) have shown … PACT SFA randomized trial evaluated the safety and …

… PACT Admiral drug-coated balloon compared with percutaneous … Drug-coated balloon vs
standard percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in …

… coated balloon (In.Pact Admiral, Invatec/Medtronic, Santa Rosa, California), maintaining a
vessel/balloon … our study, aggressive lesion preparation with an uncoated balloon prior to DEB …

… Drug-coated balloons (DCBs) have resulted in significantly higher primary patency at 6 to …
lesion length was 101.2 ± 84.2 mm. A total of 70.1% of the lesions were located in the SFA and …

… Durability of effect after treatment with a paclitaxel drug-coated balloon (DCB) for
femoropopliteal lesions: primary patency and freedom from clinically driven target lesion …

… Paclitaxel-coated balloons have consistently demonstrated … target lesion patency and reduced
clinically driven target lesion … target lesion primary patency following treatment with a drug-…

… All the presented novel innovations will certainly have their repercussions on the outcome
of endovascular treatment of SFA lesions in the near future. In order to further improve the …

… at the site of injury has become one of the most interesting … local drug delivery by a drug
coated balloon (DCb) was advanced by the finding that single-dose administration of the drug …

… A sub-analysis of lesion location showed that SFA-only lesions performed better than lesions
in the popliteal artery or SFA lesions extending into the popliteal artery. Freedom from TLR …

… When stratified according to anatomic location, lesions in the SFA-only had a patency rate …
%, and SFA lesions extending into the PA 65.9 ± 6.2% and 42.5 ± 6.8%, respectively (SFA vs. …